|
A review on drug: Amantadine
|
|
| Author:
|
ANKIT KEDIYA
|
| Abstract:
|
Amantadine is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release, and blocks dopamine reuptake. This makes it therapy for Parkinson's disease (PD). In 2013, PD was present in 53 million people and resulted in about 103,000 deaths globally. Parkinson's disease typically occurs in people over the age of 60, of which about one percent is affected. Amantadine is also an anti-influenza drug, effectively inhibits the replication of all human subtypes of influenza A virus (H1N1, H2N2 and H3N2) both in laboratory studies and in a variety of clinical situations in young and old persons. Worldwide, influenza A (H3N2) virus is predominant. This review article provides an evaluation of the literature on the concomitant use of amantadine available. The efficacy, safety, tolerability, and patient quality of life of this regimen are discussed. A summary of the Mechanism of action of amantadine, as well as its effects during pregnancy are also reviewed.
|
| Keyword:
|
NMDA receptor Parkinsonism influenza amantadine dopamine
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|